This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project
Satoh, Masayuki,
Ishikawa, Hiroyasu,
Meguro, Kenichi,
Kasuya, Masashi,
Ishii, Hiroshi,
Yamaguchi, Satoshi
Deficits in the cholinergic system are pronounced in dementia with Lewy bodies (DLB) and are more severe in patients with visual hallucinations (VHs). The aim is to identify the occipital glucose metabolism patterns by positron emission tomography (PET) and the changes following donepezil treatment. 13 DLB patients with VHs were enrolled in the study. After […]
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, Tomohiko,
Hanyu, Haruo,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Sakurai, Hirofumi,
Iwamoto, Toshihiko
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. We randomly assigned 42 patients to either the group treated with 15-30 […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study
Utumi, Yushi,
Iseki, Eizo,
Murayama, Norio,
Nozawa, Motohiro,
Kumagai, Ryo,
Matsubara, Youichiro,
Ichimiya, Yosuke,
Arai, Heii
Background: Functional gastrointestinal symptoms are frequently found in elderly dementia patients. In such a case, we attempt treatment by the administration of antidepressants or second-generation antipsychotics. However, these medications have a risk of side-effects. In the present study, we carried out oral administration of Rikkunshi-to to elderly dementia patients with appetite loss, and examined its […]
Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment
Tsolaki, Magda,
Kounti, Fotini,
Agogiatou, Christina,
Poptsi, Eleni,
Bakoglidou, Evangelia,
Zafeiropoulou, Myrto,
Soumbourou, Aikaterini,
Nikolaidou, Evdokia,
Batsila, Georgia,
Siambani, Aikaterini,
Nakou, Stella,
Mouzakidis, Christos,
Tsiakiri, Anna,
Zafeiropoulos, Stavros,
Karagiozi, Konstantina,
Messini, Chaido,
Diamantidou, Alexandra,
Vasiloglou, Maria
Background: Mild cognitive impairment (MCI) patients are at increased risk of developing dementia. There is a conflict if cognitive interventions can improve cognitive and functional performances in order to delay the development of dementia.; Objectives: This study aimed to examine the effectiveness of a holistic cognitive rehabilitation program on patients with MCI.; Methods: The participants, […]
Systematic care for caregivers of patients with dementia: a multicenter, cluster-randomized, controlled trial
Spijker, Anouk,
Wollersheim, Hub,
Teerenstra, Steven,
Graff, Maud,
Adang, Eddy,
Verhey, Frans,
Vernooij-Dassen, Myrra
Objective: To evaluate the effectiveness of the Systematic Care Program for Dementia (SCPD) on patient institutionalization and to determine the predictors of institutionalization.; Design: Single-blind, multicenter, cluster-randomized, controlled trial.; Setting: Six community mental health services (CMHSs) across the Netherlands.; Participants: A total of 295 patient-caregiver dyads referred to a CMHS with suspected patient dementia.; Intervention: […]
The effects of behavioral activation therapy with inpatient geriatric psychiatry patients
Snarski, Melissa,
Scogin, Forrest,
DiNapoli, Elizabeth,
Presnell, Andrew,
McAlpine, Jessie,
Marcinak, Jacquelyn
This study examined the effects of Behavioral Activation (BA) treatment on depressive symptoms and quality of life among older adult patients in a geriatric psychiatry facility. There were 50 participants with mild to moderate cognitive impairment, each being 65 years of age or older. A 2 (between)×3 (time of measurement) design was used in this […]
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial
Schulz, Jörg B.,
Rainer, Michael,
Klünemann, Hans-Hermann,
Kurz, Alexander,
Wolf, Stefanie,
Sternberg, Kati,
Tennigkeit, Frank
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer’s disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily […]